Skipping one gene ingredient boosts a key brain protein in Rett syndrome mice

Baylor College of Medicine / Duncan Neurological Research Institute at Texas Children's Hospital

Rett syndrome strips away skills that children have already learned. A girl who was babbling, reaching, making eye contact will, somewhere between 6 and 18 months of age, begin to lose those abilities. Motor coordination deteriorates. Speech fades. Breathing becomes irregular. The cause is almost always a mutation in a single gene called MECP2, which sits on the X chromosome and affects roughly 1 in 10,000 female births.

For years, researchers have known that the damage is reversible in principle. Restore normal MeCP2 protein to the brains of affected mice, and symptoms improve dramatically. But doing that safely in humans has proven extraordinarily difficult, because the brain is exquisitely sensitive to MeCP2 dosage. Too little causes Rett syndrome; too much causes an entirely different neurological disorder, MECP2 Duplication Syndrome. The therapeutic window is narrow.

A team at Baylor College of Medicine and the Duncan Neurological Research Institute at Texas Children's Hospital has now found what may be a way to thread that needle. Their approach, published in Science Translational Medicine, does not add a new gene. Instead, it coaxes cells to produce more protein from the gene patients already have.

Two proteins from one gene, and a dispensable ingredient

The MECP2 gene produces two slightly different versions of its protein, called E1 and E2. Both come from the same gene, but cells process the genetic instructions differently to make each one. Think of the gene as a recipe with four ingredients: e1, e2, e3, and e4. To make E1, cells use ingredients e1, e3, and e4. To make E2, they use all four, making e2 the unique component.

E1 is the dominant form in the brain. Critically, no Rett syndrome patient has ever been identified with a mutation affecting only E2, and mouse studies confirm that E2 is not required for normal brain function. That observation gave graduate student Harini Tirumala and senior author Dr. Huda Zoghbi a hypothesis: if you remove the e2 ingredient, cells should be forced to produce more E1 instead.

A 50-to-60 percent protein boost

The team first tested this idea in normal mice by genetically deleting the e2 exon from the Mecp2 gene. The result was a 50% to 60% increase in total MeCP2 protein. The mice showed no adverse neurological effects, suggesting the extra protein stayed within a safe range.

They then moved to a more clinically relevant model: cells derived from actual Rett syndrome patients carrying MECP2 mutations that reduce protein abundance or function. When the researchers deleted the e2 segment from the mutant gene in these cells, MeCP2 production increased. More importantly, depending on the severity of the original mutation, the cells recovered part or all of their normal structure, electrical activity, and ability to regulate downstream gene expression.

A synthetic molecule that mimics the effect

Genetic deletion proves the concept, but it is not a therapy. So the team tested morpholinos, synthetic molecules that can block access to specific gene segments, preventing cells from reading the e2 ingredient. In mice, the morpholinos significantly increased MeCP2 protein levels.

Morpholinos themselves carry toxicity concerns that make them unsuitable for clinical use. But the same principle could be applied using antisense oligonucleotides (ASOs), a class of synthetic molecules already approved for other neurological conditions including spinal muscular atrophy. ASOs can be delivered directly to the central nervous system and have an established safety track record.

Who this could help, and who it could not

This approach is not universal. It works by amplifying whatever mutant protein a patient's cells already produce. That means it is best suited for the roughly 65% of Rett syndrome patients whose mutations leave the MeCP2 protein partially functional, with reduced DNA binding or lower abundance rather than a completely nonfunctional protein.

For patients whose mutations produce no protein at all, or a severely truncated version, boosting production of a nonfunctional molecule would not help. Those patients would likely need gene replacement or other strategies.

The work also remains preclinical. The protein increases were measured in mice and patient-derived cell cultures, not in living patients. Whether the same exon-skipping strategy can achieve the right dosage balance in a human brain, cross the blood-brain barrier efficiently, and maintain its effect over time are all open questions.

A foundation, not a finish line

Still, the results represent a concrete step toward a treatment that works with the patient's own genetic machinery rather than trying to replace it. The fact that about two-thirds of Rett patients carry the type of mutations most likely to respond makes the potential patient population substantial for a rare disease.

The next steps will involve developing ASO-based versions of the therapy and testing them in mouse models of Rett syndrome to see whether the protein boost translates into behavioral and neurological improvement in living animals. If those results hold, human trials could follow, though Zoghbi and her team are careful to note that timeline remains uncertain.